Revenue Interest Purchase Agreement - Additional Information (Details) - Purchase Agreement - OrbiMed - USD ($)		3 Months Ended	12 Months Ended
	Sep. 12, 2022	Mar. 31, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received	$ 125,000,000
Potential revenue interest second payment to be received	$ 75,000,000
Purchase agreement, second payment date	Sep. 12, 2025
Potential revenue interest third payment to be received	$ 50,000,000
Purchase agreement, third payment date	Sep. 12, 2025
Revenue interest payment term	45 days
Amortization of purchase agreement obligation		$ 0
Effective interest rate		9.20%
Debt issuance costs		$ 600,000
Revenue interest payable		$ 2,108,000	$ 2,300,000
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue interest payment to be received	$ 125,000,000